Details

Autor(en) / Beteiligte

• Hudis, Clifford A

Titel

Trastuzumab — Mechanism of Action and Use in Clinical Practice

Ist Teil von

• The New England journal of medicine, 2007-07, Vol.357 (1), p.39-51

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall survival. Trastuzumab, a humanized monoclonal antibody that targets HER2, is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent. Trastuzumab is approved by the Food and Drug Administration for patients with invasive breast cancers that overexpress HER2. This review considers the mechanism of action and the use of this agent. Overexpression of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu or ErbB-2), a 185-kD receptor first described more than two decades ago, 1 occurs in 20 to 30% of invasive breast carcinomas. In general, patients with breast-cancer cells that overexpress this receptor or that have a high copy number of its gene have decreased overall survival and may have differential responses to a variety of chemotherapeutic and hormonal agents. 2 – 6 Thus, strategies to target HER2 appear to be important in treating breast cancer. One such medication is trastuzumab (Herceptin, Genentech), a humanized monoclonal antibody. Trastuzumab binds . . .